NCT07773818

Brief Summary

Based on the UPGRADE-TNBC study, a high-quality TNBC sample repository was established. By integrating multi-source data-including clinical information, radiomics, pathological images, and molecular sequencing-and innovatively incorporating a meta-learning strategy, a treatment response prediction model based on multimodal small-sample learning was developed. This approach aims to optimize drug combinations and precisely identify patient subgroups likely to benefit from treatment, thereby providing a new paradigm for personalized therapy in early-stage TNBC.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for all trials

Timeline
35mo left

Started Aug 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress5%
Aug 2026Sep 2029

Study Start

First participant enrolled

August 6, 2026

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

August 16, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 19, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2028

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2029

Last Updated

August 19, 2026

Status Verified

August 1, 2026

Enrollment Period

2.1 years

First QC Date

August 16, 2026

Last Update Submit

August 16, 2026

Conditions

Triple -Negative Breast CancertripleMeta-LearningPredictive ModelsMultimodal

Outcome Measures

Primary Outcomes (1)

  • Model building

    A predictive model for neoadjuvant therapy in TNBC was successfully established

    2 years

Study Arms (1)

The Population in the UPGRADE-TNBC Study（early-stage triple-negative breast cancer）

Other: Collect data

Interventions

Collect dataOTHER

Collect multi-source data from patients, including clinical information, radiomics, pathological images, and molecular sequencing

The Population in the UPGRADE-TNBC Study（early-stage triple-negative breast cancer）

Eligibility Criteria

Age18 Years - 75 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The participants in the UPGRADE-TNBC study were all patients with early-stage triple-negative breast cancer who received neoadjuvant therapy.

You may qualify if:

  • The UPGRADE-TNBC Study Population

You may not qualify if:

  • Populations outside the UPGRADE-TNBC study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral blood and tumor tissue

Central Study Contacts

Xue Wang

CONTACT

86-010-87787242wxyxyuki@163.com

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 16, 2026

First Posted

August 19, 2026

Study Start

August 6, 2026

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

September 1, 2029

Last Updated

August 19, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)